MedTrace Logo

Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging

NCT01257932 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-11-01

No results posted yet for this study

Summary

The investigators have developed imaging protocols to monitor and predict breast cancer response to neoadjuvant chemotherapy, both prior to and as early as possible during the course of treatment.

The efficacy and practicality of conventional imaging approaches in the neoadjuvant chemotherapy setting varies and identifies the need for alternate functional imaging strategies. Diffuse optical spectroscopic imaging is an experimental imaging method that allows patients to be followed from baseline through treatment and surgery with a cost-effective, bedside, handheld scanning probe. The researcher evaluates a harmonized diffuse optical spectroscopic imaging technology platform that has been standardized for neoadjuvant chemotherapy monitoring. Diffuse optical spectroscopic imaging is an academic research platform that is non-invasive. Studies will be performed in five clinical sites on approximately 60 neoadjuvant chemotherapy patients.

Conditions

Interventions

DEVICE

Diffuse Optical Spectroscopy Imaging

Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy

Sponsors & Collaborators

  • American College of Radiology Imaging Network

    collaborator NETWORK

  • Massachusetts General Hospital

    collaborator OTHER

  • University of Pennsylvania

    collaborator OTHER

  • Dartmouth-Hitchcock Medical Center

    collaborator OTHER

  • University of San Francisco

    collaborator OTHER

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • Boston University

    collaborator OTHER

  • Beckman Laser Institute University of California Irvine

    collaborator OTHER

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Bruce Tromberg, PhD · Beckman Laser Institute

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01257932 on ClinicalTrials.gov